A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors
A phase 1/2 trial of IMP1734 in advanced solid tumours, run by Eikon Therapeutics, now recruiting.
Overview
A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06253130 by Eikon Therapeutics, with 156 participants planned, started 2023-12-11 and due to reach its primary completion in 2027-06-01. Interventions recorded: IMP1734.
Similar pages
not linked directly; found by shared links- TrialA Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
Shares IMPACT Therapeutics, Eikon Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialStudy to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Shares IMPACT Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC
Shares Eikon Therapeutics and the tag pipeline.
- TreatmentEIK1001
Shares Eikon Therapeutics and the tag pipeline.
- TrialInvestigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPlasmodium Immunotherapy for Advanced Malignant Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst-in-Human Study of ICT01 in Patients With Advanced Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.